-
Migraine and Subclinical Brain Lesions; Memantine Treatment in Alzheimer Disease; PPG in Type 2 DM
-
Optimizing outcomes in patients with acute coronary syndrome requires matching patients with strategies that will produce the best results in specific clinical subgroups. Identifying those patients with ST elevation myocardial infarction (STEMI) who represent ideal candidates for fibrinolysis, and who are likely to have outcomes that are at least as favorable as they would have with percutaneous interventions, has become an area of intense focus among cardiologists and emergency physicians. Significant improvements in patient outcomes will be made when patients are managed according to their institutional capabilities, with the understanding that prompt thrombolysis in the setting of STEMI is fundamental to optimal patient care. This article, the second in a two-part series, provides a practical, evidence-based approach to comprehensive management of this patient population.
-
High-dose atorvastatin protects patients with acute coronary syndrome from death and major cardiovascular events better than usual dose pravastatin.
-
These data provide further support that inflammation in general and periodontal disease more specifically are stroke risk factors.
-
The first of a class of calcimimetics has been approved by the FDA for the treatment of hyperparathyroidism associated with renal failure and in patients with parathyroid cancer.
-
-
Increased iron stores (eg, ferritin levels) are associated with an increased risk of type 2 diabetes in women.
-
Shared pathophysiologic mechanisms for migraine, neuropathic pain, and epilepsy underscore the notion that antiepileptic drugs (AED) should be standard treatment for the former. Five new AEDs and their use in these nonepileptic painful disorders are summarized.
-
Use of B-Type Natriuretic Peptide in the Evaluation and Management of
Acute Dyspnea; Association Between C-Reactive Protein and Age-Related Macular Degeneration; VZV Reactivation in Astronauts
-